Interleukin (IL)-23 plays a central role in the orchestration of inflammatory responses. Produced by dendritic cells and macrophages, this cytokine promotes the protection of the host against mucosal pathogens through the induction of IL-17 and related cytokines by lymphoid cells. Preclinical disease models and association studies in humans have also clearly demonstrated the implication of IL-23 signalling pathway in inflammatory diseases. Indeed, this cytokine is now considered as a major therapeutic target in immune-based pathologies such as psoriasis, ankylosing spondylitis or Crohn's disease. Furthermore, in the context of inflammation-related cancer, IL-23 is thought to contribute to tumorigenesis and progression to metastatic disease. Herein, we review our current understanding of IL-23 regulation at the transcriptional and post-transcriptional levels. We discuss the relevance of these findings in the context of infection, chronic inflammation and cancer.
CITATION STYLE
Welsby, I., & Goriely, S. (2016). Regulation of interleukin-23 expression in health and disease. In Advances in Experimental Medicine and Biology (Vol. 941, pp. 167–189). Springer New York LLC. https://doi.org/10.1007/978-94-024-0921-5_8
Mendeley helps you to discover research relevant for your work.